What is Ionetix?
Ionetix is a specialized radiopharmaceutical and particle accelerator company focused on the development and operation of compact superconducting cyclotrons. These advanced systems are designed for the on-site and distributed production of critical medical radioisotopes, including PET tracers and targeted radiopharmaceuticals for cancer treatment. By enabling healthcare providers to produce these vital diagnostic imaging agents and therapeutic alpha emitters closer to the point of care, Ionetix is advancing the accessibility and efficiency of nuclear medicine.
How much funding has Ionetix raised?
Ionetix has raised a total of $31M across 2 funding rounds:
Debt
$1M
Stock/Share Issuance
$30M
Debt (2020): $1M with participation from PPP
Stock/Share Issuance (2026): $30M, investors not publicly disclosed
Key Investors in Ionetix
PPP
Public-Private Partnership
What's next for Ionetix?
The recent major strategic investment signals a new phase of growth and development for Ionetix. This capital is expected to accelerate the company's expansion, potentially funding further research into novel radiopharmaceutical applications, enhancing its cyclotron technology, and broadening its market reach. The company's focus on distributed production of PET tracers and targeted radiotherapies positions it to capitalize on the increasing demand for advanced cancer treatments and diagnostic tools.
See full Ionetix company page
